Electra Therapeutics (NASDAQ:ETRA) Coverage Initiated by Analysts at HC Wainwright

Key Points

• HC Wainwright initiated coverage of Electra Therapeutics with a “Buy” rating and a $30 price target, implying 244.43% upside from the prior close.
• Analyst sentiment is broadly positive: Electra has a consensus “Buy” rating and an average target price of $33.50, with targets ranging from $30 to $36.
• Shares opened at $8.71, near the company’s 52-week low of $8.50. Directors Orbimed Advisors and Carl L. Gordon each purchased 1.33 million shares at $15 per share, worth approximately $20 million.

Analysts at HC Wainwright initiated coverage on shares of Electra Therapeutics (NASDAQ:ETRA - Get Free Report) in a note issued to investors on Monday, Marketbeat Ratings reports. The brokerage set a "buy" rating and a $30.00 price target on the stock. HC Wainwright's target price would suggest a potential upside of 244.43% from the stock's previous close.

Several other research analysts have also recently commented on the company. Zacks Research upgraded Electra Therapeutics to a "hold" rating in a research note on Wednesday, October 14th. Jefferies Financial Group began coverage on Electra Therapeutics in a report on Tuesday, October 13th. They issued a "buy" rating and a $32.00 price target for the company. Wall Street Zen upgraded Electra Therapeutics to a "hold" rating in a research note on Saturday, September 26th. Evercore initiated coverage on Electra Therapeutics in a research note on Tuesday, October 13th. They set an "outperform" rating and a $36.00 price objective for the company. Finally, TD Cowen assumed coverage on Electra Therapeutics in a report on Tuesday, October 13th. They set a "buy" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Electra Therapeutics presently has a consensus rating of "Buy" and an average target price of $33.50.

Electra Therapeutics Stock Performance

Shares of Electra Therapeutics stock opened at $8.71 on Monday. Electra Therapeutics has a 1-year low of $8.50 and a 1-year high of $15.50.

Insider Activity

In other news, Director Orbimed Advisors Llc purchased 1,333,333 shares of the firm's stock in a transaction that occurred on Monday, September 21st. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $19,999,995.00. Following the completion of the purchase, the director owned 5,126,891 shares of the company's stock, valued at approximately $76,903,365. This trade represents a 35.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Carl L. Gordon acquired 1,333,333 shares of the stock in a transaction that occurred on Monday, September 21st. The stock was purchased at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the completion of the acquisition, the director owned 5,126,891 shares of the company's stock, valued at $76,903,365. The trade was a 35.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

About Electra Therapeutics

Electra Therapeutics, Inc NASDAQ: ETRA is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company's research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body's ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.